HomeBUSINESS
BUSINESS

Mitsubishi Tanabe’s HIF-PH Inhibitor Enters Japan PIII
(Nov.2.2017)

Mitsubishi Tanabe Pharma said on November 1 that it has launched a PIII trial in Japan for its hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor vadadustat (MT-6548), licensed from US partner Akebia Therapeutics, for the treatment of renal anemia ...
(LOG IN FOR FULL STORY)

News Calendar